Provided by Tiger Trade Technology Pte. Ltd.

Immunocore Holdings plc

32.92
+0.24000.73%
Volume:96.63K
Turnover:3.18M
Market Cap:1.66B
PE:-56.56
High:33.55
Open:32.83
Low:32.12
Close:32.68
52wk High:40.71
52wk Low:23.15
Shares:50.53M
Float Shares:37.57M
Volume Ratio:0.36
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5821
EPS(LYR):-1.0219
ROE:-7.55%
ROA:-1.55%
PB:4.19
PE(LYR):-32.21

Loading ...

Immunocore Holdings PLC expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
Yesterday

Immunocore Holdings plc published an update to their financial calendar

Reuters
·
Feb 18

Press Release: Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025

Dow Jones
·
Feb 18

Leadership Shuffle in Immunocore’s R&D Suite Might Change The Case For Investing In IMCR

Simply Wall St.
·
Feb 09

Goldman Sachs Sticks to Its Buy Rating for Immunocore Holdings (IMCR)

TIPRANKS
·
Feb 05

Immunocore Holdings Price Target Maintained With a $100.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 04

Analysts Offer Insights on Healthcare Companies: DaVita (DVA) and Immunocore Holdings (IMCR)

TIPRANKS
·
Feb 04

Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL) and Immunocore Holdings (IMCR)

TIPRANKS
·
Feb 02

Moderna CMO Jacqueline Miller to step down

Reuters
·
Jan 30

Immunocore announces EVP, Research, Development Berman to depart

TIPRANKS
·
Jan 30

Immunocore - to Streamline R&D Structure

THOMSON REUTERS
·
Jan 30

Immunocore - David Berman to Depart Immunocore

THOMSON REUTERS
·
Jan 30

Immunocore Names Mohammed Dar and Mark Moyer as Executive Vice Presidents

Reuters
·
Jan 30

A Look At Immunocore (IMCR) Valuation After J.P. Morgan Update And Analyst Upgrade

Simply Wall St.
·
Jan 12

Immunocore Announces 2026 Plans to Expand KIMMTRAK Access, Complete Phase 3 Melanoma Trials, Advance PRAME Franchise, and Initiate New Autoimmune and HIV Studies

Reuters
·
Jan 09

Immunocore announces 2026 strategic priorities

TIPRANKS
·
Jan 09

Immunocore to Present Strategic Updates at J.P. Morgan Healthcare Conference

Reuters
·
Jan 09

Immunocore Holdings Coverage Assumed by UBS at Buy vs Previous Rating of Sell

Dow Jones
·
Jan 08

UBS Upgrades Immunocore Holdings to Buy From Sell, Adjusts Price Target to $55 From $24

MT Newswires Live
·
Jan 07

Immunocore Holdings Plc : UBS Raises to Buy From Sell

THOMSON REUTERS
·
Jan 07